eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2013
vol. 38
 
Share:
Send email
Share:
abstract:

Comparison of the expression of complement regulatory proteins CD46, CD55 and CD59 in primary colon cancer and synchronous/metachronous liver metastases

Ewa Wilczek
,
Aleksander Wasiutynski
,
Grzegorz M. Wilczynski
,
Dariusz Sladowski
,
Barbara Gornicka

(Centr Eur J Immunol 2013; 38 (4): 543-548)
DOI: https://doi.org/10.5114/ceji.2013.39773
Online publish date: 2013/12/30
View full text Get citation
 
PlumX metrics:
Although recent years have brought many advantages in clinical oncology, colon cancer is still a serious problem. Surgical resection remains the most efficient treatment, but its results are not always satisfactory. To improve disease-free survival, overall survival, and to prevent metastases, new strategies for effective treatment are searched for. Immunotherapy using monoclonal antibodies was shown to be effective in some types of malignancies, however one of the most important obstacles to this type of treatment is attributed to the presence of the complement inhibitors on cancer cells. The three main membrane-bound complement inhibitors that limit the efficacy of the complement-mediated cytotoxicity on cancer cells are CD46, CD55 and CD59. In the current study, we evaluated the expression of these three complement inhibitors on colon cancer tumor samples. Additionally we compared, in samples obtained from the same patients, the immunoreactivities of these inhibitors in the primary and metastatic sites of the tumor. We found that in colon cancer cells the most common is CD46, whereas CD55 and CD59 are present in a small percentage of tumor samples. Although the staining intensity varied between primary and metastatic foci, these results, regarding all examined complement inhibitors were not statistically relevant. It appears that CD46 plays the most significant role among complement inhibitors in colon cancer. Thus, attempts should be made to inhibit this regulator when complement-mediated cytotoxicity is taken into consideration as an option for control of cancer cells remaining after surgical resection of the tumor.
keywords:

colon cancer, CD46, CD55, CD59
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.